Amylyx Pharmaceuticals Financial Statements (AMLX)
|
|
|
|
Report date
|
|
|
31.03.2022 |
13.03.2023 |
22.02.2024 |
04.03.2025 |
03.03.2026 |
|
07.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
22.2 |
380.8 |
87.4 |
0.000 |
|
0.000 |
|
Operating Income, bln rub |
|
|
-82.7 |
-201.3 |
38.8 |
-314.7 |
-153.3 |
|
-159.3 |
|
EBITDA, bln rub |
? |
|
-82.6 |
-200.9 |
39.9 |
-291.0 |
-144.2 |
|
-150.3 |
|
Net profit, bln rub |
? |
|
-87.9 |
-198.4 |
49.3 |
-301.7 |
-144.7 |
|
-150.1 |
|
|
OCF, bln rub |
? |
|
-74.8 |
-179.9 |
11.9 |
-167.6 |
-123.3 |
|
-120.4 |
|
CAPEX, bln rub |
? |
|
0.353 |
2.53 |
1.24 |
0.157 |
0.138 |
|
0.127 |
|
FCF, bln rub |
? |
|
-75.2 |
-182.4 |
10.7 |
-167.8 |
-123.5 |
|
-120.5 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
82.7 |
220.6 |
316.5 |
359.9 |
152.8 |
|
139.2 |
|
Cost of production, bln rub |
|
|
0.000 |
2.99 |
25.4 |
42.2 |
0.525 |
|
20.2 |
|
R&D, bln rub |
|
|
44.0 |
93.5 |
128.2 |
104.1 |
90.4 |
|
95.6 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
105.6 |
391.5 |
517.5 |
193.6 |
332.6 |
|
293.6 |
|
Net Assets, bln rub |
? |
|
-151.2 |
340.6 |
433.4 |
164.8 |
305.3 |
|
273.2 |
|
Debt, bln rub |
|
|
0.000 |
6.28 |
4.24 |
1.98 |
5.96 |
|
5.63 |
|
Cash, bln rub |
|
|
96.1 |
346.9 |
371.4 |
176.5 |
317.0 |
|
279.8 |
|
Net debt, bln rub |
|
|
-96.1 |
-340.7 |
-367.1 |
-174.5 |
-311.0 |
|
-274.1 |
|
|
Ordinary share price, rub |
|
|
|
37.0 |
14.7 |
3.78 |
12.1 |
|
13.3 |
|
Number of ordinary shares, mln |
|
|
57.9 |
66.5 |
67.2 |
68.1 |
94.6 |
|
110.6 |
|
|
Market cap, bln rub |
|
|
0 |
2 458 |
990 |
258 |
1 142 |
|
1 469 |
|
EV, bln rub |
? |
|
-96 |
2 117 |
623 |
83 |
831 |
|
1 195 |
|
Book value, bln rub |
|
|
-151 |
341 |
433 |
165 |
305 |
|
273 |
|
|
EPS, rub |
? |
|
-1.52 |
-2.98 |
0.73 |
-4.43 |
-1.53 |
|
-1.36 |
|
FCF/share, rub |
|
|
-1.30 |
-2.74 |
0.16 |
-2.46 |
-1.31 |
|
-1.09 |
|
BV/share, rub |
|
|
-2.61 |
5.12 |
6.45 |
2.42 |
3.23 |
|
2.47 |
|
|
EBITDA margin, % |
? |
|
|
-903.5% |
10.5% |
-333.0% |
|
|
|
|
Net margin, % |
? |
|
|
-892.4% |
12.9% |
-345.4% |
|
|
|
|
FCF yield, % |
? |
|
|
-7.42% |
1.08% |
-65.1% |
-10.8% |
|
-8.21% |
|
ROE, % |
? |
|
58.2% |
-58.2% |
11.4% |
-183.1% |
-47.4% |
|
-55.0% |
|
ROA, % |
? |
|
-83.3% |
-50.7% |
9.52% |
-155.8% |
-43.5% |
|
-51.1% |
|
|
P/E |
? |
|
0.00 |
-12.4 |
20.1 |
-0.85 |
-7.89 |
|
-9.78 |
|
P/FCF |
|
|
0.00 |
-13.5 |
92.7 |
-1.53 |
-9.25 |
|
-12.2 |
|
P/S |
? |
|
|
110.6 |
2.60 |
2.95 |
|
|
|
|
P/BV |
? |
|
0.00 |
7.22 |
2.28 |
1.56 |
3.74 |
|
5.38 |
|
EV/EBITDA |
? |
|
1.16 |
-10.5 |
15.6 |
-0.29 |
-5.77 |
|
-7.95 |
|
Debt/EBITDA |
|
|
1.16 |
1.70 |
-9.20 |
0.60 |
2.16 |
|
1.82 |
|
|
R&D/CAPEX, % |
|
|
12 476% |
3 700% |
10 329% |
66 296% |
65 510% |
|
75 312% |
|
|
CAPEX/Revenue, % |
|
|
|
11.4% |
0.33% |
0.18% |
|
|
|
|
| Amylyx Pharmaceuticals shareholders |
